Kumar Devendra, Trivedi Neerja, Dixit Rakesh K
Department of Pharmacology and Therapeutics, King George's Medical University, Lucknow, Uttar Pradesh, India; Department of Biotechnology, Dr. APJ Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India.
Center of Biomedical Research, SGPGIMS Campus, Lucknow, Uttar Pradesh, India.
J Intercult Ethnopharmacol. 2016 Sep 21;6(1):68-74. doi: 10.5455/jice.20160902023435. eCollection 2017 Jan-Mar.
AIMS/BACKGROUND: This study was evaluated synergistic effect of a polyherbal formulation (PHF) of L., Lam., L., Linn., and L. on p-glycoprotein (Pgp) of intestine. These five herbs were traditionally used for diabetes. These herbs are commonly present in Ayurvedic product as antidiabetics in India.
PHF was prepared by five indigenous herbs. Different doses (50, 100 and 200 mg/kg/day) of were orally administered to Sprague-Dawley rats of different groups for multiple weeks except control groups. Alteration in Pgp expression was evaluated by real-time-polymerase chain reaction and western blotting while modulation in activity of Pgp was evaluated using rhodamine 123 (Rh123) as transport substrate by absorption and everted gut sac method.
In PHF, pretreated group received 50, 100 and 200 mg/kg/day for 7 days, mRNA level decreased by 1.75, 2.45 and 2.37-fold, respectively, as compared to control. Similarly, when PHF at dose of 100 mg/kg/day was given consequently for 4 weeks, maximum decrease in Pgp expression level was observed only after 1 week and further increase in the treatment duration did not produce significant decrease compared to the 1 week treatment. Pgp mediated transport of Rh123 was significantly decreased with everted gut sac prepared from PHF pretreated rats (1 week) compared to those prepared from vehicle treated rats.
We report that PHF pretreatment downregulated the expression of intestinal Pgp and this downregulated intestinal Pgp would result in decreased functional activity. In addition, this downregulated Pgp expression might affect the bioavailability of antidiabetic Pgp substrate drugs.
目的/背景:本研究评估了由[植物名称1]、[植物名称2]、[植物名称3]、[植物名称4]和[植物名称5]组成的多草药配方(PHF)对肠道P-糖蛋白(Pgp)的协同作用。这五种草药传统上用于治疗糖尿病。在印度,这些草药通常作为抗糖尿病药物存在于阿育吠陀产品中。
PHF由五种本土草药制备而成。除对照组外,将不同剂量(50、100和200毫克/千克/天)的[草药名称]口服给予不同组的斯普拉格-道利大鼠数周。通过实时聚合酶链反应和蛋白质免疫印迹法评估Pgp表达的变化,同时使用罗丹明123(Rh123)作为转运底物,通过吸收法和外翻肠囊法评估Pgp活性的调节。
在PHF预处理组中,分别以50、100和200毫克/千克/天的剂量给药7天,与对照组相比,mRNA水平分别下降了1.75倍、2.45倍和2.37倍。同样,当以100毫克/千克/天的剂量连续给予PHF 4周时,仅在1周后观察到Pgp表达水平的最大下降,与1周治疗相比,治疗持续时间的进一步延长并未产生显著下降。与载体处理大鼠制备的外翻肠囊相比,PHF预处理大鼠(1周)制备的外翻肠囊中Pgp介导的Rh123转运显著降低。
我们报告称,PHF预处理下调了肠道Pgp的表达,这种下调的肠道Pgp将导致功能活性降低。此外,这种下调的Pgp表达可能会影响抗糖尿病Pgp底物药物的生物利用度。